The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer.
Austin K MattoxChristopher B DouvilleYuxuan WangMaria PopoliJanine PtakNatalie SillmanLisa DobbynJoy SchaeferSteve LuAlexander H PearlmanJoshua David CohenJeanne TiePeter GibbsKamel LahouelChetan BettegowdaRalph H HrubanCristian TomasettiPeiyong JiangAllen K C ChanYuk Ming Dennis LoNickolas PapadopoulosKenneth W KinzlerBert VogelsteinPublished in: Cancer discovery (2023)
cfDNA concentrations from patients with cancer are often elevated compared to that of healthy controls, but the sources of this extra cfDNA have never been determined. To address this issue, we assessed cfDNA methylation patterns in 178 patients with cancers of the colon, pancreas, lung, or ovary and 64 patients without cancer. Eighty-three of these individuals had cfDNA concentrations much greater than those generally observed in healthy subjects. The major contributor of cfDNA in all samples was leukocytes, accounting for ~76% of cfDNA, with neutrophils predominating. This was true regardless of whether the samples were derived from patients with cancer or the total plasma cfDNA concentration. High levels of cfDNA observed in patients with cancer did not come from either neoplastic cells or from surrounding normal epithelial cells from the tumor's tissue of origin. These data suggest that cancers may have a systemic effect on cell turnover or DNA clearance.
Keyphrases
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- single cell
- stem cells
- cell therapy
- cell proliferation
- electronic health record
- young adults
- machine learning
- bone marrow
- prognostic factors
- patient reported outcomes
- big data
- cell death
- circulating tumor
- bone mineral density
- circulating tumor cells